Alexander Russell-Smith, Louise Murphy, Amy Nguyen, Cori Blauer-Peterson, Marilou Terpenning, Feng Cao, . . . Richa Shah. (2023). Real-world use of inotuzumab ozogamicin is associated with lower health care costs than blinatumomab in patients with acute lymphoblastic leukemia in the first relapsed/refractory setting. Becaris Publishing Limited.
Chicago Style (17th ed.) CitationAlexander Russell-Smith, et al. Real-world Use of Inotuzumab Ozogamicin Is Associated with Lower Health Care Costs than Blinatumomab in Patients with Acute Lymphoblastic Leukemia in the First Relapsed/refractory Setting. Becaris Publishing Limited, 2023.
MLA (9th ed.) CitationAlexander Russell-Smith, et al. Real-world Use of Inotuzumab Ozogamicin Is Associated with Lower Health Care Costs than Blinatumomab in Patients with Acute Lymphoblastic Leukemia in the First Relapsed/refractory Setting. Becaris Publishing Limited, 2023.